TECH Stock Cash Flow Statements

Bio-Techne Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Bio-Techne Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2016-09-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2011-09-30

cash flows from operating activities:
net earnings	-17,678,000	22,588,000	34,890,000	33,600,000														45,403,000	46,143,000	33,395,000	58,845,000	36,433,000	119,620,000	14,398,000	16,460,000	44,654,000	17,555,000	17,403,000	41,701,000	19,739,000	48,429,000	16,281,000	30,291,000	25,852,000	22,707,000	26,329,000	23,907,000	26,824,000	31,641,000	25,055,000	27,428,000	28,411,000	33,118,000	25,364,000	25,668,000	27,521,000
adjustments to reconcile net earnings to net cash from operating activities:
depreciation and amortization	27,111,000	27,571,000	27,084,000	28,137,000	28,057,000	27,311,000	27,803,000	28,540,000	26,923,000	26,971,000	26,703,000	26,641,000	25,866,000	25,367,000	25,102,000	24,734,000	24,672,000	21,103,000	20,884,000	21,088,000	20,991,000	21,108,000	20,553,000	20,085,000	19,919,000	19,322,000	19,878,000	19,052,000	17,152,000	16,273,000	17,394,000	13,644,000	10,828,000	10,590,000	10,685,000	9,499,000	8,559,000	5,311,000	4,918,000	4,856,000	4,090,000	3,042,000	3,001,000	3,173,000	3,105,000	3,135,000
costs recognized on sale of acquired inventory	197,000	181,000	185,000	188,000	179,000	186,000	183,000	181,000	0	0	100,000	300,000	0	0	84,000	1,512,000	1,474,000	68,000							935,000	935,000	934,000	935,000	442,000	1,431,000	-3,637,000	4,219,000	1,082,000	1,244,000	1,113,000	1,709,000	3,167,000	3,168,000	1,177,000	1,404,000	1,731,000	1,005,000	1,032,000	1,200,000	1,264,000	2,148,000
deferred income taxes	-32,282,000	-5,408,000	-8,077,000	-5,340,000	-9,551,000	-7,582,000	-10,723,000	-11,591,000	-6,916,000	-16,286,000	-1,598,000	-4,767,000	-1,072,000	655,000	1,826,000	5,407,000	-21,408,000	-6,239,000	668,000	-452,000	4,489,000	-6,164,000	15,412,000	-607,000	-2,468,000	-2,008,000	-5,338,000	-3,768,000	1,314,000	-4,493,000	-42,367,000	-1,170,000	57,000	-321,000	-1,115,000	2,098,000	-1,617,000	1,245,000	-1,092,000	-1,677,000	-1,329,000	-480,000	-567,000	-710,000	-777,000	-1,066,000
stock-based compensation expense	4,550,000	11,391,000	14,708,000	10,184,000	7,063,000	8,133,000	12,753,000	10,093,000	-2,085,000	10,110,000	16,744,000	14,461,000	8,406,000	8,071,000	13,969,000	11,737,000	9,808,000	10,643,000	15,578,000	12,953,000	6,017,000	7,855,000	10,129,000	8,366,000	8,129,000	5,725,000	6,861,000	11,565,000	14,653,000	4,748,000	5,663,000	3,176,000	2,317,000	2,321,000	2,038,000	1,232,000	1,362,000	888,000	740,000	1,326,000	569,000	490,000	286,000	785,000	303,000	290,000
fair value adjustment to contingent consideration payable					0	0	-1,750,000	-1,750,000	-1,750,000	-1,750,000	-8,500,000	-100,000	200,000	-4,200,000	-13,600,000	-2,800,000	-888,000	1,588,000	4,750,000	-150,000	-300,000	-705,000	-600,000	700,000	-900,000	-400,000	-500,000	-200,000	0	200,000	18,000,000	1,900,000
gain on sale of ccxi investment
(gain) loss on equity method investment	-1,107,000	589,000	-46,000	-374,000		1,747,000	1,913,000	2,382,000
asset impairment restructuring	11,351,000	120,000	3,802,000	6,039,000									0	0	0	546,000
gain on sale of eminence									0	0	0	-11,682,000
leases	183,000	10,000	47,000	445,000	-124,000	636,000	583,000	613,000	625,000	794,000	-1,905,000	2,545,000	-227,000	-473,000	-422,000	-79,000	-8,000	-30,000
impairment of assets held-for-sale					15,925,000	0
other operating activity	148,000	222,000	-442,000	747,000	162,000	166,000	74,000	182,000	159,000	184,000	144,000	-32,000	119,000	166,000	-114,000	497,000	144,000	-932,000	129,000	195,000	-58,000	-866,000	28,000	164,000	70,000	-85,000	123,000	2,217,000	-888,000	108,000
change in operating assets and operating liabilities, net of acquisition:
trade accounts and other receivables	28,861,000	-15,669,000	-623,000	21,563,000	-17,922,000	-22,944,000	4,734,000	15,599,000	-92,000	-32,200,000	-5,910,000	17,335,000	3,334,000	-51,583,000	-5,710,000	-3,637,000	17,161,000	-30,383,000	-3,237,000	910,000	3,864,000	-7,258,000	11,355,000	-1,405,000				8,307,000	-12,099,000	-9,237,000	28,812,000	-10,176,000	-20,029,000	9,176,000	-3,763,000	-4,431,000	422,000	8,007,000	-9,753,000	2,997,000	-106,000	-15,000	-5,964,000	2,592,000	1,053,000	1,591,000
inventories	-6,604,000	173,000	-8,908,000	-2,805,000	-4,616,000	-22,000	-4,361,000	-5,216,000	-1,351,000	-10,454,000	-7,677,000	-10,685,000	-15,973,000	-7,334,000	-5,719,000	-2,981,000	-3,025,000	-3,529,000	1,382,000	-1,968,000	-4,852,000	-5,628,000	-3,661,000	-720,000	-2,097,000	-3,338,000	-1,534,000	-6,678,000	-1,751,000	-4,063,000	-5,099,000	-2,414,000	322,000	-1,383,000	-3,176,000	168,000	-2,326,000	-2,191,000	539,000	-947,000	-296,000	-184,000	-670,000	-278,000	-1,084,000	-226,000
prepaid expenses	-7,155,000	-6,812,000	2,753,000	-3,158,000	-1,163,000	1,166,000	-577,000	-2,572,000	972,000	-3,552,000	755,000	-2,760,000	494,000	3,449,000	-1,173,000	-5,852,000									302,000	1,258,000			1,924,000	-463,000	716,000	605,000	464,000	-744,000	-766,000	-25,000	8,000	-516,000	-69,000	336,000	-305,000	207,000	-47,000	59,000	-252,000	-145,000
trade accounts payable, accrued expenses, contract liabilities, and other	-13,315,000	-610,000	10,882,000	-10,911,000	18,609,000	1,778,000	8,077,000	-2,695,000	-2,261,000	5,894,000	-10,140,000	-1,401,000	1,512,000	11,404,000	2,128,000	-2,303,000		3,574,000	1,706,000	6,918,000		2,916,000	5,659,000	1,456,000
salaries, wages and related accruals	3,402,000	8,124,000	12,128,000	-8,246,000	5,455,000	11,468,000	-2,148,000	-2,157,000	-1,799,000	10,506,000	-4,905,000	-28,360,000	5,701,000	12,467,000	8,525,000	-18,933,000	6,707,000	15,542,000	9,767,000	-11,480,000	7,642,000	5,095,000	798,000	-10,983,000	5,115,000	3,835,000	4,539,000	-8,476,000	4,070,000	-4,613,000	7,711,000	-7,257,000	2,883,000	717,000	-1,704,000	986,000	2,528,000	-429,000	1,320,000	-1,277,000	1,420,000	-728,000	1,026,000	-790,000	400,000	825,000
income taxes receivable	16,381,000
net cash from operating activities	98,201,000	41,120,000	84,346,000	63,889,000	75,496,000	80,986,000	83,116,000	59,383,000	83,393,000	50,535,000	64,384,000	56,081,000	102,717,000	73,128,000	100,993,000	48,434,000	122,020,000	74,866,000	89,269,000	66,009,000	44,791,000	49,469,000	70,418,000	40,539,000	55,946,000	39,662,000	46,563,000	39,448,000	64,839,000	21,650,000	57,376,000	26,502,000	37,137,000	38,539,000	31,833,000	37,139,000	35,718,000	37,921,000	34,934,000	31,322,000	32,585,000	29,987,000	33,025,000	31,287,000	29,263,000	34,432,000
capex	-4,890,000	-10,123,000	-6,821,000	-9,172,000	-17,980,000	-16,441,000	-14,864,000	-13,592,000	-10,831,000	-11,748,000	-6,109,000	-9,556,000	-13,570,000	-15,100,000	-10,168,000	-6,070,000	-11,316,000	-10,602,000	-11,445,000	-10,938,000	-17,373,000	-9,282,000	-14,564,000	-10,525,000	0	-4,925,000	0	-4,190,000	0	-3,508,000	0	-2,442,000	-2,836,000	-4,887,000	-6,121,000	-6,934,000	-4,905,000	-2,102,000	-4,261,000	-3,647,000	-3,811,000	-5,346,000	-6,373,000	-8,220,000	-2,515,000	-1,096,000
free cash flows	93,311,000	30,997,000	77,525,000	54,717,000	57,516,000	64,545,000	68,252,000	45,791,000	72,562,000	38,787,000	58,275,000	46,525,000	89,147,000	58,028,000	90,825,000	42,364,000	110,704,000	64,264,000	77,824,000	55,071,000	27,418,000	40,187,000	55,854,000	30,014,000	55,946,000	34,737,000	46,563,000	35,258,000	64,839,000	18,142,000	57,376,000	24,060,000	34,301,000	33,652,000	25,712,000	30,205,000	30,813,000	35,819,000	30,673,000	27,675,000	28,774,000	24,641,000	26,652,000	23,067,000	26,748,000	33,336,000

cash flows from investing activities:
proceeds from sale of available-for-sale investments	0	0	0	1,085,000	4,324,000	0	0	23,759,000
purchases of available-for-sale investments					0	0			0	0	-6,000,000	-14,500,000	-5,000,000	-34,498,000	0	-13,500,000		-12,500,000	-945,000	-26,239,000		-25,629,000	-9,228,000	-15,871,000		-11,693,000	-14,306,000	-11,694,000		0
proceeds from sale of ccxi investment									0	0	0	73,219,000
additions to property and equipment	-4,890,000	-10,123,000	-6,821,000	-9,172,000	-17,980,000	-16,441,000	-14,864,000	-13,592,000	-10,831,000	-11,748,000	-6,109,000	-9,556,000	-13,570,000	-15,100,000	-10,168,000	-6,070,000	-11,316,000	-10,602,000	-11,445,000	-10,938,000	-17,373,000	-9,282,000	-14,564,000	-10,525,000				-4,190,000				-2,442,000	-2,836,000	-4,887,000	-6,121,000	-6,934,000	-4,905,000	-2,102,000	-4,261,000	-3,647,000	-3,811,000	-5,346,000	-6,373,000	-8,220,000	-2,515,000	-1,096,000
acquisitions, net of cash acquired					0	0	-3,281,000	-166,426,000	0	0	0	-101,184,000					-215,587,000	0							-17,206,000	1,000	-58,000	-272,229,000	-2,785,000	-54,422,000	248,360,000	-259,004,000	-8,000,000	82,000	-82,970,000	0	-360,175,000	-6,031,000
distributions from (investments in) wilson wolf			0	1,403,000	4,848,000	0	0	2,149,000
proceeds from sale of eminence									0	0	0	17,824,000
investment in spear bio	0	0	0	-15,000,000
proceeds from sale of assets held-for-sale	658,000	0
net cash from investing activities	406,000	-8,873,000	-5,032,000	-21,684,000	-8,808,000	-16,441,000	-23,671,000	-154,110,000	-4,756,000	-241,096,000	-109,000	-19,688,000	-18,570,000	-35,993,000			-226,903,000	129,000	-8,604,000	-8,138,000	-10,473,000	19,358,000	33,295,000	-15,085,000	-30,316,000	-4,736,000	-13,634,000	-288,113,000	37,968,000	-57,930,000	249,532,000	-268,282,000	-13,986,000	-4,805,000	-85,161,000	-5,522,000	-354,754,000	163,685,000	-81,000	-8,783,000	-105,133,000	-4,759,000	-11,525,000	-9,000,000	-5,920,000	-10,449,000
cash flows from financing activities:
cash dividends	-12,387,000	-12,580,000	-12,736,000	-12,688,000	-12,627,000	-12,579,000	-12,559,000	-12,654,000	-12,597,000	-12,582,000	-12,561,000	-12,545,000	-12,539,000	-12,577,000	-12,576,000	-12,493,000	-12,448,000	-12,446,000	-12,392,000	-12,336,000	-12,258,000	-12,279,000	-12,196,000	-12,169,000	-12,127,000	-12,086,000	-12,085,000	-12,066,000	-12,032,000	-11,995,000	-12,014,000	-11,932,000	-11,902,000	-11,902,000	-11,894,000	-11,888,000	-11,472,000	-11,469,000	-11,440,000	-11,434,000	-11,051,000	-11,050,000	-11,053,000	-11,048,000	-10,312,000	-10,026,000
proceeds from stock option exercises	6,226,000	14,872,000	5,540,000	25,101,000	22,934,000	18,331,000	5,276,000	14,394,000	8,414,000	4,422,000	5,027,000	11,950,000	8,809,000	11,846,000	18,620,000	37,880,000	10,100,000	22,655,000	16,919,000	15,418,000	32,493,000	11,243,000	18,295,000	8,952,000	10,921,000	8,169,000	2,407,000	16,453,000	5,446,000	7,025,000	4,673,000	2,026,000	748,000	47,000	1,128,000	-1,000	1,864,000	3,198,000	1,568,000	2,415,000	1,145,000	281,000	0	688,000	136,000	45,000
re-purchases of common stock	-100,057,000	-100,046,000			0	0			0	0	0	-19,562,000	-58,818,000	-60,838,000											0	-1,000
borrowings under line-of-credit agreement	66,000,000				0	0	65,000,000	160,000,000	0	170,000,000	0	449,661,000	0	40,000,000	40,000,000	10,000,000													0	30,000,000	-318,500,000	343,500,000	0	0	77,000,000	0	125,000,000
repayments of long-term debt	-50,000,000	-8,000,000	0	-19,000,000	-70,000,000	-58,000,000	-58,000,000	-70,000,000	-20,000,000	0	-64,661,000	-441,000,000		-63,125,000	-58,125,000	-51,125,000		-16,125,000	-92,125,000	-33,125,000		-3,125,000	-103,125,000	-19,125,000				-357,125,000
taxes paid on rsus and net share settlements	-234,000	-291,000	-1,013,000	-4,984,000	-402,000	-168,000	-1,074,000	-20,228,000	-39,000	-11,001,000	0	-17,853,000
other financing activity									0	0	0	-2,457,000	23,406,000	629,000	-1,000	-23,246,000		-6,133,000	-2,481,000	-4,890,000		-114,000	-1,000	-1,927,000				-1,727,000
net cash from financing activities	-90,452,000	-68,045,000	-83,837,000	-11,571,000	-60,095,000	-52,416,000	-81,399,000	71,512,000	-24,222,000	150,839,000	-72,195,000	-31,806,000	-65,728,000	-84,065,000	-53,376,000	-39,684,000	117,688,000	-55,227,000	-90,079,000	-34,933,000	-44,720,000	-17,786,000	-97,027,000	-24,269,000	-19,897,000	-27,043,000	-41,207,000	222,531,000	-62,832,000	-952,000	-277,738,000	242,334,000	-19,535,000	-13,366,000	41,865,000	-85,677,000	102,470,000	-8,009,000	-9,912,000	-8,983,000	-9,902,000	-12,584,000	-11,048,000	-10,297,000	-10,748,000	-21,556,000
effect of exchange rate changes on cash and cash equivalents	13,361,000	-1,081,000	-5,468,000	5,115,000	5,283,000	-2,346,000	3,423,000	-8,693,000	-1,126,000	2,322,000	7,345,000	-11,897,000	-6,673,000	-4,094,000	3,075,000	-4,400,000	150,000	842,000	5,536,000	-159,000	811,000	-5,117,000	3,715,000	-2,180,000	-407,000	1,791,000	-510,000	-1,182,000	-4,593,000	2,382,000	-5,126,000	5,248,000	-355,000	-6,758,000	5,773,000	2,145,000	-3,763,000	1,368,000	260,000	990,000	2,520,000	429,000	-3,025,000	491,000	1,535,000	-805,000
net change in cash and cash equivalents	21,516,000	-36,879,000	-9,991,000	35,749,000	11,876,000	9,783,000	-18,531,000	-31,908,000	53,289,000	-37,400,000	-575,000	-7,310,000	11,746,000	-51,024,000	15,524,000	-2,770,000
cash and cash equivalents at beginning of period	0	0	0	151,791,000	0	0	0	180,571,000	0	0	0	172,567,000	0	0	0	199,091,000		0	0	146,625,000		0	0	100,886,000		0	0	121,990,000		0	27,375,000	64,237,000	0	0	54,532,000		318,568,000		0	0	163,786,000		0	0	116,675,000	77,613,000
cash and cash equivalents at end of period	21,516,000	-36,879,000	-9,991,000	187,540,000	11,876,000	9,783,000	-18,531,000	148,663,000	53,289,000	-37,400,000	-575,000	165,257,000	11,746,000	-51,024,000	15,524,000	196,321,000		20,610,000	-3,878,000	169,404,000		45,923,000	10,402,000	99,891,000		9,675,000	-8,788,000	94,674,000		-34,850,000	51,869,000	69,589,000	3,261,000	13,610,000	48,842,000		98,239,000		25,201,000	14,546,000	83,856,000		7,427,000	12,481,000	130,805,000	79,235,000
fair value adjustment on available-for-sale investments					0	0	0	-283,000	681,000
impairment (recovery) of assets held-for-sale
distributions from wilson wolf
supplemental disclosure of cash flow information:
cash paid for income taxes		18,306,000	21,103,000	16,490,000		7,201,000	4,848,000	32,797,000		36,172,000	11,519,000	14,892,000		7,597,000	3,298,000	12,070,000		6,950,000	4,973,000	6,034,000		17,814,000	4,585,000	2,452,000		7,502,000	10,688,000	8,447,000		3,230,000
cash paid for interest		4,401,000	4,626,000	5,205,000		3,807,000	4,080,000	4,506,000		154,000	2,210,000	3,409,000		2,378,000	3,037,000	3,107,000		2,950,000	3,542,000	4,237,000		4,327,000	4,777,000	5,092,000		5,298,000	7,583,000	3,229,000		3,247,000
income taxes payable			-4,037,000	-6,180,000	-10,599,000	9,885,000	13,051,000	-22,936,000	-6,340,000	-9,587,000	10,496,000	2,939,000	11,875,000	-3,108,000	13,718,000	-19,818,000	9,898,000	-454,000	5,365,000	-1,383,000	-17,386,000	-2,231,000	11,153,000	1,233,000	-1,051,000	429,000	-4,034,000	-4,864,000	11,983,000	5,593,000	-10,222,000	2,850,000	1,794,000	-7,436,000	6,204,000	-967,000	1,127,000	-5,085,000	3,796,000	-741,000	91,000	-1,955,000	2,134,000	-234,000	-782,000	-1,449,000
net earnings, including noncontrolling interest					40,588,000	49,058,000	27,466,000	50,993,000	75,484,000	70,219,000	50,005,000	89,734,000	61,915,000	60,144,000	72,059,000	68,981,000
contingent consideration payments - operating													0
loss on equity method investment
eminence impairment													0	0
investment of forward purchase contract													0	0
contingent consideration payments - financing													0
proceeds from maturities of available-for-sale investments									6,075,000	2,652,000	12,000,000	14,509,000	0	13,605,000	0	12,450,000				29,039,000				11,311,000		11,881,000				0				0	3,930,000		9,880,000	12,681,000	12,561,000	18,103,000	16,090,000	8,116,000	31,665,000	10,721,000	11,601,000	24,763,000
investment in unconsolidated entity																	0
investment in wilson wolf									0
(gain) loss on investment										0	0	-37,176,000
fair value adjustment on available for sale investments											72,000	-911,000	567,000	18,103,000	-28,395,000	-5,277,000	57,645,000	16,590,000	-10,707,000	4,351,000	-26,260,000	-411,000	-121,257,000	10,401,000	18,974,000	-12,273,000	7,164,000	2,202,000
gain on escrow settlement
payments on line-of-credit																													-53,500,000	0	85,513,000	-91,513,000	-8,500,000	-1,500,000	-24,500,000		-13,000,000
contingent consideration payments															0	-3,300,000	-182,000	0
other investing activity
net cash provided by investing activities																-7,120,000
net earnings, including non-controlling interest
change in operating assets and liabilities, net of acquisitions:
trade accounts payable and accrued expenses																									-1,876,000	2,592,000			3,361,000	6,401,000	-8,868,000	4,132,000	7,561,000	-1,655,000	-416,000	664,000	-1,487,000	793,000	1,569,000	-166,000	-828,000	458,000	-475,000	42,000	218,000	1,598,000
proceeds from sale and maturities of available-for-sale investments																	0	23,231,000			24,453,000	54,269,000
purchase of available-for-sale investments																																					0	-17,463,000	-17,406,000	-44,867,000	-27,010,000	-23,613,000	-46,479,000	-21,501,000	-21,119,000	-34,311,000
other investing activities
other financing activities
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
other current assets																		1,922,000	-3,140,000	1,632,000		70,000	1,229,000	-2,549,000				-1,354,000
re-purchase of common stock
proceeds from long-term debt																												580,000,000
net increase in cash and cash equivalents																		20,610,000				45,924,000				9,675,000					24,494,000	5,352,000	3,261,000						25,201,000	14,546,000	-79,930,000		7,427,000	12,481,000	14,130,000	1,622,000
net decrease in cash and cash equivalents																				22,779,000				-995,000				-27,316,000							-5,690,000		-220,329,000
contingent consideration payable
payment of contingent consideration
debt issuance costs																												-3,004,000
gain on investment
excess tax benefit from stock option exercises																																253,000	119,000	-11,000	131,000	-1,007,000	78,000	-262,000	40,000	-36,000	-4,000	-6,000	-5,000	-63,000	-1,000	-7,000
payments of contingent consideration																														8,800,000
impairment of investment
accounts receivable																										-20,984,000
purchases of property and equipment																										-4,925,000				-3,508,000
borrowings under credit agreement																										0
payments on credit agreement																										-23,125,000
other financing																										0				-2,182,000
trade accounts payable, accrued expenses, and contract liabilities																												3,107,000
contingent consideration
purchase of equity investment
other																																262,000	-433,000	178,000	26,000	492,000	68,000	168,000	108,000	192,000	124,000	426,000	125,000	105,000	107,000	19,000
proceeds from available-for-sale investments
purchases of available for sale investments																																-6,836,000
gain on cyvek acquisition
net proceeds from maturities and purchases of available-for-sale investments
distributions from unconsolidated entities																																	0	0	0		446,000
gain on sale of cyvek
net (gain) income from equity method investees
purchase of common stock for stock bonus plans																																						0	0	0	0	0	0	0	-573,000	-907,000
repurchase of common stock																																										-1,821,000	0	0	0	-10,675,000
payment on line-of-credit and other
proceeds from sales of available-for-sale investments																																					0		9,030,000	21,645,000	12,700,000		9,830,000	10,337,000	6,200,000	10,195,000
payments on line of credit and other
impairment losses on investments																																										0
increase in other long-term assets																																							-5,000	83,000	-138,000	-151,000	-168,000	-337,000	-87,000	-10,000,000
losses by equity method investees																																								0	0		31,000	42,000	41,000	198,000
acquisition, net of cash acquired																																								-100,000	-103,049,000
distribution from unconsolidated entity																																								0	85,000	1,095,000	0
change in operating assets and operating liabilities:
impairment loss on investments
increase in other assets
trade, other accounts payable and accrued expenses
income taxes payable/receivable

We provide you with 20 years of cash flow statements for Bio-Techne stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Bio-Techne stock. Explore the full financial landscape of Bio-Techne stock with our expertly curated income statements.

The information provided in this report about Bio-Techne stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.